SCHEMBL4967428

SCHEMBL4967428

O=[N+]([O-])c1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCOCCOCCOCCO

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 4/20 0.74
▸ EGFR P00533 16/20 0.70
▸ KDR P35968 2/20 0.54
▸ HDAC3 O15379 1/20 0.54
▸ HDAC4 P56524 1/20 0.54
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC7 Q8WUI4 1/20 0.54
▸ HDAC2 Q92769 1/20 0.54
▸ HDAC10 Q969S8 1/20 0.54
▸ HDAC11 Q96DB2 1/20 0.54
▸ HDAC8 Q9BY41 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ HDAC9 Q9UKV0 1/20 0.54
▸ HDAC5 Q9UQL6 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.53
▸ GAK O14976 1/20 0.53
▸ MAPK13 O15264 1/20 0.53
▸ ABL1 P00519 1/20 0.53
▸ ERBB2 P04626 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4966928 1.00 FBP1 (0.74) FBP1EGFRKDRHDAC3HDAC4
SCHEMBL5115038 1.00 FBP1 (0.74) FBP1EGFRKDRHDAC3HDAC4
SCHEMBL1418145 0.94 FBP1 (0.79) FBP1EGFRKDRHDAC3HDAC4
SCHEMBL4968390 0.93 FBP1 (0.74) FBP1EGFRKDRKDM4EGAK
SCHEMBL4968762 0.93 FBP1 (0.74) FBP1EGFRKDRKDM4EGAK
SCHEMBL1417946 0.92 FBP1 (0.78) FBP1EGFRKDRHDAC3HDAC4
SCHEMBL1419978 0.91 FBP1 (0.76) FBP1EGFRKDRHDAC3HDAC4
SCHEMBL4967436 0.89 FBP1 (0.58) FBP1EGFRKDRERBB2ABCG2
SCHEMBL4968744 0.89 FBP1 (0.58) FBP1EGFRKDRERBB2ABCG2
SCHEMBL4968371 0.89 FBP1 (0.58) FBP1EGFRKDRERBB2ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461166-B2 Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2013-06-11 — — US disclosed
EP-1957468-A2 POLYALKYLENE GLYCOL DERIVATIVES OF 4 - (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE T.K. Signal Ltd. (IL) 2008-08-20 — — EP disclosed
US-20080056990-A1 Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase T.K. SIGNAL LTD. (IL) 2008-03-06 — — US disclosed
WO-2007029251-A2 POLYALKYLENE GLYCOL DERIVATIVES OF 4- (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GR0WTH FACT0R RECEPTOR TYROSINE KINASE T.K. SIGNAL LTD. (IL) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080056990-A1 Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase EGFR, TK1, ERBB2 FBP1 1341/4885EGFR 1/4885KDR 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback